Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lyell Immunopharma (LYEL) Return on Equity (2020 - 2025)

Lyell Immunopharma's Return on Equity history spans 5 years, with the latest figure at 1.06% for Q2 2025.

  • For Q2 2025, Return on Equity fell 72.0% year-over-year to 1.06%; the TTM value through Jun 2025 reached 1.06%, down 72.0%, while the annual FY2024 figure was 0.65%, 34.0% down from the prior year.
  • Return on Equity for Q2 2025 was 1.06% at Lyell Immunopharma, down from 0.94% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.18% in Q1 2021 and bottomed at 1.06% in Q2 2025.
  • The 5-year median for Return on Equity is 0.26% (2022), against an average of 0.35%.
  • The largest annual shift saw Return on Equity grew 11bps in 2022 before it tumbled -72bps in 2025.
  • A 5-year view of Return on Equity shows it stood at 0.22% in 2021, then grew by 2bps to 0.22% in 2022, then tumbled by -52bps to 0.33% in 2023, then tumbled by -122bps to 0.73% in 2024, then tumbled by -45bps to 1.06% in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Return on Equity are 1.06% (Q2 2025), 0.94% (Q1 2025), and 0.73% (Q4 2024).